-
5m 58sPart 3 | Session 2 ALL-RISE – Coronary Physiology From Angiography vs Pressure Wire for PCI
-
6m 28s
-
8m 35sPart 3 | Session 4 The STEMI-DTU Trial – Primary Unloading and Delayed Reperfusion in STEMI
-
4m 47s
-
13m 52sPart 3 | Session 6 ACC 2026 with Dr Mehran: Leadership, Vision, and the Future of the College
-
5m 17sPart 3 | Session 7 Heart Failure in 2026: Practical Therapy Lessons From ACC.26
-
6m 14sPart 3 | Session 8 RECOVER-Autonomic - Ivabradine for Post-COVID POTS
-
9m 23sPart 3 | Session 9 ORBITA-CTO - PCI Versus Placebo for Chronic Total Occlusion in Stable Angina
-
7m 21sPart 3 | Session 10 CHIP-BCIS3 – Percutaneous LV Unloading in High-Risk PCI
-
16m 1sPart 3 | Session 11 Dr Reddy & Dr Nair on CHAMPION-AF: Redefining Stroke Prevention
-
7m 26sPart 3 | Session 12 FAST III - FFR vs vFFR to Guide Revascularisation
-
5m 34sPart 3 | Session 13 AI-Based Retinal Imaging for Atherosclerotic Cardiovascular Risk
-
4m 5sPart 3 | Session 14 CORALreef — Durability of Enlicitide for Lipid Lowering in Hypercholesterolaemia
-
5m 18sPart 4 | Session 1 STEMI-DTU, GOFRESH, and HI-PEITHO
-
3m 7sPart 4 | Session 2 SURPASS CVOT, HI-PEITHO, SURVIV
-
5m 8sPart 4 | Session 3 Top Takeaways from the 2026 Dyslipidaemia Guidelines
-
2m 21sPart 4 | Session 4 3 ACC.26 Highlights for the Cardiology Pharmacist
-
10m 19s
-
25m 1sPart 1 | Session 1 CHAMPION-AF: LAA Closure vs OAC in AF Outcomes
-
18m 33sPart 1 | Session 2 ALERT: Under-treatment in AS and MR
-
26m 37sPart 1 | Session 3 PRO-TAVI: TAVI With or Without Routine PCI
-
19m 43sPart 1 | Session 4 Dig-RHD: Digoxin in Rheumatic Heart Disease
-
6m 44sPart 2 | Session 1 VESALIUS-CV, KARDINAL, CHIP-BCIS3 & More
-
9m 4sPart 2 | Session 2 CHAMPION-AF, HI-PEITHO, STEMI-DTU
ACC 2026 — Dr Babar Mir Basir (Henry Ford Hospital, Detroit, MI, USA) and Dr Karim Al-Azizi (Baylor Scott & White Health, The Heart Hospital, Plano, TX, USA) come together to discuss the Door to Unload Randomized Clinical Trial, examining what the findings mean for the management of acute myocardial infarction and the evolving role of mechanical circulatory support in high-risk patients.
In this expert exchange, Drs Basir and Al-Azizi explore the clinical implications of the trial, debating how its results should inform decision-making around LV unloading strategies and where the evidence now points for interventional practice.
Recorded at ACC 2026.
Editors: Jordan Rance, Mirjam Boros
Videographer:
Support: This is an independent video produced by Radcliffe Cardiology.
Keep up-to-date with our video collection from the American College of Cardiology's 75th Annual Scientific Session, bringing you the latest from late-breaking science, featured research, and clinical horizon sessions.
Catch our congress preview and wrap-up in the NVM Cardiology Meeting Reflections series, alongside concise Expert Interviews with leading faculty distilling the key take-home messages for clinical practice — plus in-depth Highlights breaking down the most impactful trials of the meeting.
More from this programme
Part 1
Late-Breaker Discussions
Part 2
Between the Sessions with Dr Purvi Parwani
Part 3
Expert Interviews
Part 4
Highlights
Part 5
Market Watch
Part 6
NVM Cardiology Meeting Reflections
Faculty Biographies
Babar Basir
Interventional Cardiologist
Dr Mir Basir is an Interventional Cardiologist at the Henry Ford Hospital in Detroit, Michigan, US.
Dr Basir specialises in the treatment of complex heart blockage with minimally invasive techniques using balloons and stents. He is a national leader in the treatment of cardiogenic shock and lectures around the world on the use of temporary heart pumps when the heart is failing.
Karim Al-Azizi
Interventional Cardiologist and Structural Heart Disease Specialist
Dr Karim Al-Azizi is an Interventional Cardiologist and Structural Heart Disease specialist at Baylor Scott & White Health - The Heart Hospital, Texas, USA. He serves as the Medical Director of the Structural Heart Program and the Cardiac Catheterization Laboratories. He serves as the Program Director of the Structural Heart Disease Fellowship.
His clinical and research interests include structural heart disease, transcatheter interventions for valvular heart disease, and electrosurgery. He speaks at national and international conferences on these subjects and serves as a principal investigator on multiple clinical trials in structural heart disease.
Comments